Tempest Therapeutics Raises Substantial Doubt About Going-Concern Status
The company disclosed substantial doubt about its ability to continue as a going concern.
Related stories
Lucara Q3 Revenue Rises 19%; 2026 Guidance Raised to $140M–$160M
Q3 revenue rose 19% to $61.1 million from $51.2 million in Q3 2025, primarily due to a 1,303-carat Type IIa diamond sale. The company raised 2026 revenue guidance to $140 million–$
M impact | EQUITY | Nov 13, 2026, 10:46 PM UTC
LIVESTOCK-CME feeder cattle futures reach two-week high
LIVESTOCK-CME feeder cattle futures reach two-week high By Tom Polansek CHICAGO, Nov 13 (Reuters)
L impact | EQUITY | Nov 13, 2026, 10:37 PM UTC
Nasdaq Determines to Delist SHF Holdings Shares Over Low Price
Nasdaq has determined to delist SHF Holdings shares due to their low price.
M impact | EQUITY | Nov 13, 2026, 10:33 PM UTC
FAA Grounds Flights, Airline Shares Decline Late in Session
The FAA halted flights, citing “extraordinary circumstances and for reasons of safety.” American Airlines closed down 1% at $13.17 and was recently trading at $12.94 after hours.
M impact | EQUITY | Nov 13, 2026, 10:22 PM UTC
US Airlines Fall in Extended Trading Amid Nationwide Ground Stop
American Airlines, Delta and United fell more than 1%; JetBlue fell 3%.
M impact | EQUITY | Nov 13, 2026, 10:22 PM UTC
Douglas Elliman Names Heather Capriola CFO; James Kirkland Retires
Douglas Elliman appointed Heather Capriola CFO as James Kirkland retires.
L impact | EQUITY | Nov 13, 2026, 10:18 PM UTC